Navigation Links
A leukemia drug kills cancerous T-cells while sparing normal immunity
Date:1/25/2012

BOSTON, MALeukemic cutaneous T-cell lymphoma (L-CTCL) is a leukemia arising from T-cells, a type of white blood cell. This cancer can involve the skin and other organs, and patients often die within three years.

Rachael A. Clark, MD, PhD, BWH assistant professor of dermatology and associate dermatologist and Thomas Kupper, MD, BWH Department of Dermatology chairman and their colleagues now report a new study that low-dose Campath (alemtuzumab) not only treats patients with L-CTCL but does so without increasing their risk of infections.

The study was electronically published on January 18, 2012 in Science Translational Medicine.

Campath was previously believed to kill all lymphocytes (T-cells and B-cells) in the body and render patients susceptible to infections. However, Clark and Kupper found that Campath only kills T-cells that enter the bloodstream, but it spares a newly discovered population of T-cells that live long-term in the tissues.

"We noticed that our patients were not getting infections, and we looked in the skin. We saw healthy T-cells remaining there despite the fact that there were no T-cells in the blood," said Clark. "We used to believe that most T-cells responsible for protecting against infection were in the bloodstream. But we now realize that highly protective T-cells also inhabit tissues such as the skin, lungs and gastrointestinal tract. It is these tissue resident T-cells that are critical in protecting us from infection on a day-to-day basis."

By showing that Campath kills circulating T-cells, including the cancerous T-cells, but spares tissue resident T-cells, Clark and Kupper have shown that Campath effectively treats L-CTCL while sparing normal immunity. Their findings are also the first demonstration in human beings that tissue resident T-cells provide frontline immune protection of the skin.

"We're very grateful to our patients for entrusting us with their care and for teaching us important lessons about the immune system." said Clark.

In a companion piece, Mark Davis, PhD, Stanford University School of Medicine, called the work a "translational tour de force."


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Penn researchers find genetic link to leukemias with an unknown origin
2. High Rates of Childhood Leukemia Seen in Iraq Province
3. International study confirms doubling of childhood leukemia rates in southern Iraq
4. Cells of aggressive leukemia hijack normal protein to grow
5. Targeting leukemia cells gene addiction presents new strategy for treatment
6. 2010 recipient of Minority Scholar Award will conduct clinical research on leukemia
7. 2010 Recipient of Minority Scholar Award Will Conduct Clinical Research on Leukemia
8. New gateway to treat leukemia and other cancers
9. Targeting cell pathway may prevent relapse of leukemia
10. Autograph Store Sponsors The Leukemia Ball Charity Auction
11. Leukemia-related protein 16 and colorectal carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... Scottsdale, AZ (PRWEB) , ... ... ... pioneer, ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus ... , WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg Leyer, the ... Probiotic Association’s Washington DC workshop on November 2nd. The conference was an opportunity ... probiotic dietary supplement regulations. , Dr. Leyer spoke about two main topics ...
(Date:12/6/2016)... ... 2016 , ... The International Vaccine Institute (IVI) and GeneOne ... Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development ... in the event of a future outbreak. , IVI and GeneOne held a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, Inc. ... biology company focused on delivering scientific and medical ... that Chairman and Chief Executive Officer Keith ... on Wednesday, December 14, 2016 at 1:00 p.m. ... are not yet familiar with the Company, an ...
(Date:12/7/2016)... 7, 2016 The global  ... value of USD 3.9 billion by 2024, based ... Inc. The growth of the market is attributed ... technological advancements by the market players. Demand for ... increasing donation, rising awareness about transfusion-transmitted diseases, and ...
(Date:12/6/2016)... 2016 Diabetes & Obesity Drug Development Pipeline ... disease cluster is currently dominated by therapeutics indicated for ... mellitus (T2DM), and the majority of the pipeline, in ... attributable to these indications. While products indicated for obesity ... are a large number of these products in the ...
Breaking Medicine Technology: